BioTelemetry Inc.
Find Ratings Reports
-0.73 |
-1.50%
BIOTELEMETRY INC's gross profit margin for the first quarter of its fiscal year 2019 is essentially unchanged when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. BIOTELEMETRY INC has strong liquidity. Currently, the Quick Ratio is 1.74 which shows the ability to cover short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 28.89% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
| Income Statement | Q1 FY19 | Q1 FY18 |
|---|---|---|
| Net Sales ($mil) | 103.98 | 94.5 |
| EBITDA ($mil) | 26.27 | 21.65 |
| EBIT ($mil) | 16.25 | 11.82 |
| Net Income ($mil) | 11.69 | 5.98 |
| Balance Sheet | Q1 FY19 | Q1 FY18 |
|---|---|---|
| Cash & Equiv. ($mil) | 45.49 | 36.35 |
| Total Assets ($mil) | 659.99 | 528.03 |
| Total Debt ($mil) | 221.74 | 203.7 |
| Equity ($mil) | 333.01 | 258.35 |
| Profitability | Q1 FY19 | Q1 FY18 |
|---|---|---|
| Gross Profit Margin | 67.62 | 67.26 |
| EBITDA Margin | 25.26 | 22.9 |
| Operating Margin | 15.63 | 12.51 |
| Sales Turnover | 0.62 | 0.62 |
| Return on Assets | 7.35 | -1.92 |
| Return on Equity | 14.57 | -3.93 |
| Debt | Q1 FY19 | Q1 FY18 |
|---|---|---|
| Current Ratio | 1.99 | 1.96 |
| Debt/Capital | 0.4 | 0.44 |
| Interest Expense | 2.48 | 1.89 |
| Interest Coverage | 6.55 | 6.25 |
| Share Data | Q1 FY19 | Q1 FY18 |
|---|---|---|
| Shares outstanding (mil) | 33.8 | 32.79 |
| Div / share | 0.0 | 0.0 |
| EPS | 0.32 | 0.17 |
| Book value / share | 9.85 | 7.88 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 458314.0 | 663165.0 |
BUY. The current P/E ratio indicates a significant discount compared to an average of 106.92 for the Health Care Providers & Services industry and a significant premium compared to the S&P 500 average of 22.66. For additional comparison, its price-to-book ratio of 4.87 indicates a premium versus the S&P 500 average of 3.44 and a premium versus the industry average of 3.42. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAT 35.56 | Peers 106.92 | BEAT 19.84 | Peers 18.47 | |||||||||||||||||||||
|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. BEAT is trading at a significant discount to its peers. |
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. BEAT is trading at a valuation on par to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| BEAT 22.86 | Peers 14.75 | BEAT 0.63 | Peers 0.84 | |||||||||||||||||||||
|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. BEAT is trading at a significant premium to its peers. |
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. BEAT trades at a significant discount to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| BEAT 4.87 | Peers 3.42 | BEAT 509.09 | Peers -2.47 | |||||||||||||||||||||
|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. BEAT is trading at a significant premium to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. BEAT is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| BEAT 3.97 | Peers 1.71 | BEAT 25.68 | Peers 14.21 | |||||||||||||||||||||
|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. BEAT is trading at a significant premium to its industry. |
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share. BEAT has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
